

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6627763/jie-ni-publications-by-citations.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40 papers	1,862 citations	23 h-index	43 g-index
49 ext. papers	2,353 ext. citations	6.8 avg, IF	4.94 L-index

#	Paper	IF	Citations
40	Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. <i>Cell Death and Disease</i> , <b>2013</b> , 4, e875	9.8	252
39	PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. <i>Cell Death and Disease</i> , <b>2014</b> , 5, e1437	9.8	205
38	Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2013</b> , 45, 2736-48	5.6	122
37	Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 96, 507-17	7	121
36	Cancer stem cell in breast cancer therapeutic resistance. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 69, 152-163	14.4	108
35	CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. <i>Prostate</i> , <b>2014</b> , 74, 602-17	4.2	97
34	Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. <i>BMC Cancer</i> , <b>2019</b> , 19, 618	4.8	85
33	Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 55771-55788	3.3	74
32	Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis. <i>Theranostics</i> , <b>2020</b> , 10, 2309-2326	12.1	70
31	Cancer stem cells and signaling pathways in radioresistance. <i>Oncotarget</i> , <b>2016</b> , 7, 11002-17	3.3	69
30	The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. <i>Cancer and Metastasis Reviews</i> , <b>2013</b> , 32, 535-51	9.6	60
29	Role of the EpCAM (CD326) in prostate cancer metastasis and progression. <i>Cancer and Metastasis Reviews</i> , <b>2012</b> , 31, 779-91	9.6	53
28	Urinary biomarkers in prostate cancer detection and monitoring progression. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 118, 15-26	7	49
27	Targeting MicroRNAs in Prostate Cancer Radiotherapy. <i>Theranostics</i> , <b>2017</b> , 7, 3243-3259	12.1	48
26	Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 145, 102860	7	47
25	Cancer stem cells in prostate cancer chemoresistance. <i>Current Cancer Drug Targets</i> , <b>2014</b> , 14, 225-40	2.8	41
24	Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach. <i>Scientific Reports</i> , <b>2017</b> , 7, 41834	4.9	35

23	Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression. <i>Theranostics</i> , <b>2019</b> , 9, 4130-4140	12.1	35
22	Exosomes and breast cancer drug resistance. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 987	9.8	35
21	Exosomes in Cancer Radioresistance. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 869	5.3	33
20	Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. <i>PLoS ONE</i> , <b>2013</b> , 8, e74253	3.7	30
19	Triple-negative breast cancer therapeutic resistance: Where is the AchillesSheel?. <i>Cancer Letters</i> , <b>2021</b> , 497, 100-111	9.9	30
18	Cancer stem cells in prostate cancer radioresistance. <i>Cancer Letters</i> , <b>2019</b> , 465, 94-104	9.9	27
17	Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro. <i>Cancer Letters</i> , <b>2013</b> , 329, 17-26	9.9	22
16	Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy. <i>Oncotarget</i> , <b>2016</b> , 7, 74269-74285	3.3	21
15	Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo. <i>BMC Cancer</i> , <b>2018</b> , 18, 1092	4.8	19
14	Monitoring Prostate Tumor Growth in an Orthotopic Mouse Model Using Three-Dimensional Ultrasound Imaging Technique. <i>Translational Oncology</i> , <b>2016</b> , 9, 41-45	4.9	14
13	A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1612	8.4	13
12	Clinical Evaluation and Patient Satisfaction of Single Zirconia-Based and High-Noble Alloy Porcelain-Fused-to-Metal Crowns in the Esthetic Area: A Retrospective Cohort Study. <i>Journal of Prosthodontics</i> , <b>2016</b> , 25, 526-530	3.9	9
11	Enhanced osteointegration of tantalum-modified titanium implants with micro/nano-topography. <i>RSC Advances</i> , <b>2017</b> , 7, 46472-46479	3.7	8
10	In Vivo 3D MRI Measurement of Tumour Volume in an Orthotopic Mouse Model of Prostate Cancer. <i>Cancer Control</i> , <b>2019</b> , 26, 1073274819846590	2.2	5
9	Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy. <i>Expert Review of Proteomics</i> , <b>2016</b> , 13, 905-915	4.2	5
8	Quality Assessment and Comparison of Plasma-Derived Extracellular Vesicles Separated by Three Commercial Kits for Prostate Cancer Diagnosis. <i>International Journal of Nanomedicine</i> , <b>2020</b> , 15, 10241-10256	7.3	4
7	Endoplasmic Reticulum Stress and Tumor Microenvironment in Bladder Cancer: The Missing Link. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 683940	5.7	4
6	CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo. <i>Experimental Cell Research</i> , <b>2020</b> , 388, 111850	4.2	3

5	The CD44 Isoforms in Prostate Cancer Metastasis and Progression <b>2013</b> , 1, 3-14	3
4	THOC2 and THOC5 Regulate Stemness and Radioresistance in Triple-Negative Breast Cancer. <i>Advanced Science</i> , <b>2021</b> , 8, e2102658	13.6 2
3	CHTOP in Chemoresistant Epithelial Ovarian Cancer: A Novel and Potential Therapeutic Target. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 557	5.3 1
2	Activation of the eIF2 $\alpha$ /ATF4 axis drives triple-negative breast cancer radioresistance by promoting glutathione biosynthesis. <i>Redox Biology</i> , <b>2021</b> , 43, 101993	11.3 1
1	Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance. <i>Journal of the National Cancer Center</i> , <b>2021</b> , 1, 75-75	1